DNMT inhibitor Guadecitabine (SGI-110) (NCT01752933) and decitabine (NCT01799083) were assessed in phase I/II trial for pretreated patients with advanced HCC, in which decitabine showing beneficial clinical response and favorable toxicity profiles.463 A phase Ib evaluation for combination of guadecitabine with PD-L1 antibody durvalumab (NCT03257761) is underway. This evidence concerns the gene CD274 and hepatocellular carcinoma.